Skip to main content
. 2024 May 9;11:1330907. doi: 10.3389/fmed.2024.1330907

Table 1.

Demographic status and clinicopathology.

Overall (n = 28,290) GTR (n = 4,318) SpTR (n = 8,159)
Age, median (range), y 64 (55–73) 63 (54–70) 62 (53–71)
Tumor size, median (range), mm 45 (33–56) 45 (33–56) 45 (33–56)
Sex
Female 11,852 (41.9%) 1819 (42.1%) 3,316 (40.6%)
Male 16,438 (58.1%) 2,499 (57.9%) 4,843 (59.4%)
Race
White 25,394 (89.8%) 3,900 (90.3%) 7,378 (90.4%)
Others 2,896 (10.2%) 418 (9.7%) 781 (9.6%)
Married
Yes 18,050 (63.8%) 2,867 (66.4%) 5,466 (67.0%)
No 10,240 (36.2%) 1,451 (33.6%) 2,693 (33.0%)
Urban
Yes 24,873 (87.9%) 3,849 (89.1%) 7,204 (88.3%)
No 3,417 (12.1%) 469 (10.9%) 955 (11.7%)
Area of the United States
Midwest 18,276 (64.6%) 2,867 (66.4%) 5,263 (64.5%)
East 4,720 (16.7%) 672 (15.6%) 1,583 (19.4%)
South 5,008 (17.7%) 755 (17.5%) 1,250 (15.3%)
Oversea 286 (1.0%) 24 (0.6%) 63 (0.8%)
Income (US dollar)
Lower than $55,000 8,198 (29.0%) 1,325 (30.7%) 2026 (24.8%)
Higher than $55,000 20,092 (71.0%) 2,993 (69.3%) 6,133 (75.2%)
Location
Frontal 7,981 (28.2%) 1,305 (30.2%) 2,351 (28.8%)
Temporal 7,044 (24.9%) 1,302 (30.2%) 2,440 (29.9%)
Parietal 4,583 (16.2%) 786 (18.2%) 1,374 (16.8%)
Occipital 1,223 (4.3%) 236 (5.5%) 379 (4.6%)
Cerebellum 1,219 (4.3%) 66 (1.5%) 142 (1.7%)
Brainstem 120 (0.4%) 5 (0.1%) 12 (0.1%)
Ventricle 96 (0.3%) 12 (0.3%) 20 (0.2%)
Overlapping 6,024 (21.3%) 606 (14.0%) 1,441 (17.7%)
Laterality
Left 11,538 (40.8%) 1875 (43.4%) 3,139 (38.5%)
Mid 4,629 (16.4%) 275 (6.4%) 1,342 (16.4%)
Right 12,123 (42.9%) 2,168 (50.2%) 3,678 (45.1%)
Tumor extension
Confined 21,523 (76.1%) 3,727 (86.3%) 6,664 (81.7%)
Ventricles 1,119 (4.0%) 132 (3.1%) 312 (3.8%)
Midline 4,493 (15.9%) 353 (8.2%) 948 (11.6%)
Metastasis
Yes 398 (1.4%) 30 (0.7%) 73 (0.9%)
No 27,892 (98.6%) 4,288 (99.3%) 8,087 (99.1%)
BCSS
Alive 4,686 (16.6%) 729 (16.9%) 1,288 (15.8%)
Dead 23,604 (83.4%) 3,589 (83.1%) 6,871 (84.2%)

GTR, gross total resection; SpTR, supratotal resection; BCSS, brain cancer-specific survival.